Analyst Price Target is $37.13
▲ +271.62% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for TCR2 Therapeutics in the last 3 months. The average price target is $37.13, with a high forecast of $55.00 and a low forecast of $11.00. The average price target represents a 271.62% upside from the last price of $9.99.
Current Consensus is
The current consensus among 8 polled investment analysts is to buy stock in TCR2 Therapeutics. This Buy consensus rating has held steady for over two years.
TCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It also involves in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded by Patrick A. Baeuerle in May 2015 and is headquartered in Cambridge, MA.